Advanced Search

 

Study ID Status Title Patient Level Data
ILI108621 Completed A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer Study Listed on ClinicalStudyDataRequest.com
IND 001/2008 Completed A double blind randomized controlled trial in school going children, to evaluate the impact of a multiple micronutrient fortified nutritional powder on physical performance measures
ING111207 Completed A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects
ING111322 Completed GSK1349572 Repeat Dose Escalation Study
INO102141 Completed A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthmatic response in subjects with mild asthma.
IP2107882 Completed A single-centre, randomized, double-blind , placebo controlled, dose escalating cross-over study to evaluate the safety, tolerability and pharmacokinetics of single inhaled doses of GSK610677 and placebo in healthy male subjects
IPA101985 Completed A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmatic response in subjects with mild asthma
IPA106620 Completed A double blind, placebo controlled, repeat dose study to determine the effect of GSK256066 87.5 mcg to protect against AMP challenge in the lung in mild steroid-naive asthmatics.
IPA107948 Completed A randomized, double-blind, double-dummy, placebocontrolled,three-period, incomplete block, crossover study, to a investigate the effect of 14 days repeat inhaled dosing with GSK256066 in mild/moderate asthmatic patients.
IPC101939 Completed A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of inhaled GSK256066 in mild to moderate COPD patients
IPC103711 Completed A double blind, placebo controlled, repeat dose study to compare the effectiveness of two doses of GSK256066 with placebo in reducing lung inflammation following segmental LPS challenge in healthy volunteers
IPI100477 Completed A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
IPR101987 Completed A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in subjects with seasonal allergic rhinitis (SAR)
IPR107498 Completed An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
IPR109764 Completed A randomised, open, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).
IPR110723 Completed An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
IPR110982 Completed A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
ISO105774 Completed Single-blind, placebo-controlled, randomized study testing single ascending doses of GSK369796 in healthy subjects
ITG20001 Completed A Phase II, randomized, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral doses of S-1360 versus placebo over 10 days in ART-naive HIV-1 infected adults.
ITI101711 Completed A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery
ITI103221 Terminated A Study to Evaluate the Effect of Repeat Oral Doses of Odiparcil on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin.
ITI105316 Completed Randomized, single blind, parallel study to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.
ITZ111682 Completed A Single Dose, Randomized Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1265744 in Healthy Male and Female Subjects
KG2104940 Completed A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabetes mellitus
KG2105246 Completed A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects with Type 2 Diabetes Mellitus.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.